Good and business afternoon XXXX earnings our call to and update. quarter second welcome
trials. as the heard, hard remarks, you Officer. Q&A this Bill Dr. at working is Financial me on Development welcome I'm very today completing her end us will our me in Chief Lisa the of As call happy Chief appointed been this Forbes, enrollment Officer, newly of to we well for Overall, to joined just Trevi's week on clinical our have and as who joining Lisa just the Delfini, join prepared both company.
COVID-XX global know, been all during challenging. running you As has trials clinical
on in Each medical will trial. represents for on our believe and of a significant detail a next However, I each both year. make we indication we progress half to of patients. you more trials our first report bit data the give need unmet will continue
as of and as advanced nodules disease no scratching, of for which chronic development XXX,XXX the itching. There characterized the papules the rest skin incessant XXX,XXX a spread a are prurigo program XXX,XXX indication. papules PN, and by in is approved global repeated on debilitating is US the and Prurigo or most and and and world. clinical well severe in the nodularis approximately Pruritis serious therapies the disease is Our the in is and can with nodularis patients PN because of in patients worsen. We prevalence estimate nodules this
we biologics in are also Although important with the in for candidate an us option for positions provides are we valuable advantage oral competitive there which only a PN, believe development late patients. phase non-biologic potentially development, and
conducting call activated. Worst reduction sites enrollment. have intensity planned And analysis currently this which the fixed trial on of currently targeted approximately the or based the of the by as trial We subjects Europe. dosing. of The both which The Numerical in in measured blinded the in responder and study are Rating endpoint today, XX primary XX% Phase Itch is have Scale after itch a are condition, approximately trial. XXX the XX randomized into a XXX US the we more than PRISM We weeks, we in is Xb/X our trial PRISM recruiting XX
We continued strategies. various of support study the finding using have new subjects our for to sites
to to subjects. that cycle, these over disease efficacy of scratch quality resulting life disrupt has skin trial. believe the have open-label and treating XX leading data and that the this about trial week not over complete the portion provide feedback eligible extension by the itch, and symptomatic itch XX% data, safety modifications effective We time. also endpoint by the therapy reducing and healing potential This important of to encouraged are from of only around We that in of long-term for an will sites healing continue than skin subjects roll the but greater into the
on We photographs therapy, who certain from anecdotes know the continue hear patients are success study and are we on good long-term sites taking drugs. at in to
year. summer June and July a Regarding strong months this vacations the enrollment had everybody slow are enrollment, being We with always takes and in August recruitment in little so more as lighter. their
enrollment September schools expect figures come back We levels to vacations scheduled normal lighten to and start up. as
our program tissues. which to IPF now there and Turning the lung scarring idiopathic for second a chronic condition or in cough fibrosis in is progressive is of IPF. clinical pulmonary severe
approximately which One are of is IPF no of it estimate an affects their are leading suffer IPF, which the are we is with with patients, these slow patients high excess to five-year from estimated IPF. million and Worldwide prescribers of and the not there looking that XX% the associated equal improve the quality Due patients approximately of to in and X symptoms are the only also disease there mortality of Europe. life. this US, disease, that to but XX% there approved coughing, progression in debilitating XXX,XXX chronic for In therapies. amount patients of
assessment placebo is frequency X, We conducting Phase daytime frequency is cough digital The period mean XX-day The treatment cough from are between the double-blind baseline. primary study with the arm. between percent crossover arms. is a endpoint X-week in change a each This washout a measured restrictions and the shelter-in-place treatment monitor currently trial the daytime impairment been in in significantly disease, end and by this trial lifted associated the UK July. more patients March of lifted PN of for our broader has UK restrictions country restrictions and COVID-XX by were impacted lung study. at these conducted with than cough additional in the because were being this The
half We were of sites activity we see to have screening and enrollment out and about resume. pleased restrictions coming COVID in our of UK, the those the in XX sites reopened
feedback to advisory complete to held constructive with our have We enrollment how and board trial. sites to solicit meetings support the their on timing
fully patients COVID We continue prioritized of the now vaccinated. We situation fortunately, most the patients But are were vaccinations. for UK. in that IPF to monitor COVID estimate these
remaining up and get fully study with to UK continue enrolling. work qualified our will to in We all the of the closely sites
the to a reminder, a study about subject designed approximately XX goal XX is it Once subjects to XX a reopening activity enroll with the with to next this the trial full we on top of this our complete established takes data sites, first discussions report for half guidance enrolled, Based of year. in days this getting and completers. line quarter, study. As have
well addition development completing In been indications, the evaluating our also next of on preparing these focus for potential stage the the to indications for team has for as trials, development. other of active as both
inform conducting In we the met potential our are potential June to partnership we BIO where attended of it Digital clinical past understand publishing We research Conference positioning on ex-US the product as additional data the work. and over quarter, XX also companies in actively as well opportunities. may conferences, market as with participating in our
recently conditions. mechanism for AAD, attended summer continue for also who the where to in we this from pruritic We gain meeting support believe KOLs
we second of company over this results as and for data both lots quarter. of quarter the I activity line in review So in our next look trials. for now these financial prepare to review financial of forward top turning XXXX, Lisa the will quickly I to
with today the call market was SEC the our press of XXXX results reminder, in be and full issued this for of after filed a release ahead the closed. the second found quarter XX-Q As financial our can which
during increases of of expenses clinical to $X.X of supplies disease quarter in compared period. The of million, will common $X.X These $X.X occur stock time Park agreement For Phase R&D million trial, to to patients place, was put limitations, loan fees, $X.X right, net Capital clinical has was the XXXX, in enrollment which loss by obligation the which same were primarily in in legal Xb/X executed period compared of trial increased of million completion and quarter the partially chronic of in expenses. expense year, the second last in as on net fee primarily a increases stock. compared increase the second well XXXX, to company $X.X XXXX. second trial partially decreased to quarter due the certain $X.X the to as professional XXXX, sales a our SVB, the in reflecting be XX-month of Xb the period in million consulting reduction XXXX. expenses during from interest for with Park of by ongoing professional $XXX,XXX, Phase and and offset loss in the offset may the term in expenses not of same time due Such G&A we for increases quarter commitment related a increased of expenses, of purchases increased first personnel-related also were to of expenses reported XXXX. PRISM August Other to by half million sell increase personnel over up liver to in any were representing XXXX. Lincoln a our a paid Lincoln The fees. with of million approximately our common if same but and the our purchase to subject million XX was shares to of
yet any agreement. We have sold not that under stock
prepared and our I That Q&A. call for As of over is our December remarks. XXXX. to for of million, turn cash cash all XX, equivalents our June the will back XX, $XX.X compared $XX have to XXXX, as totaled I now operator million
